Shots:
- The P-III trial evaluated CagriSema (SC; QW), a fixed-dose combination of cagrilintide & semaglutide, at two dose levels (2.4mg/2.4mg & 1mg/1mg) vs semaglutide (2.4 & 1mg), cagrilintide (2.4mg) alone, & PBO in 2,728 pts with T2D inadequately controlled with metformin ± an SGLT2 inhibitor
- At 68wks., CagriSema (2.4/2.4mg) outperformed semaglutide (2.4mg), reducing HbA1c by 1.91% vs 1.76% (vs 0.09% with PBO) & body weight by 14.2% vs 10.2% (vs 1.5%), with no weight-loss plateau; 43% pts achieved ≥15% & 24% pts reached ≥20% weight loss
- Using the treatment-regimen estimand, CagriSema reduced HbA1c by 1.80% vs 1.68% & body weight by 12.9% vs 9.2%. Novo is planning regulatory discussions for T2D, with REIMAGINE 2 data due in 2026 & FDA submission already filed for weight management
Ref: Novo Nordisk | Image: Novo Nordisk | Press Release
Related News: Novo Nordisk Reports the US FDA Approval of Oral Wegovy for Weight Management
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
